Revive Therapeutics Ltd. announced that Tessio Rebello, Ph.D., will join the Company as a clinical advisor for the Company. Dr. Rebello previously held the position of Vice President of Clinical Development at VIRxSYS Corporation where he led the successful launch of anti-sense, gene therapy (VRX496), Phase 2 clinical trial for the treatment of HIV-infected patients who fail to respond to conventional drug therapies and two other Phase 2 clinical trials involving the same drug.